COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00532519
Recruitment Status : Unknown
Verified September 2007 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : September 20, 2007
Last Update Posted : September 20, 2007
Information provided by:
Hadassah Medical Organization

Brief Summary:

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.

Condition or disease Intervention/treatment Phase
Prurigo Nodularis Drug: citalopram (cipralex) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Intervention Details:
  • Drug: citalopram (cipralex)
    10-20 mg/day, for 12 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

Exclusion Criteria:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00532519

Layout table for location contacts
Contact: Liran Horev, MD OO97226777111 LIRAN_CH@BEZEQINT.NET

Layout table for location information
: Hadassah Medical Organization,
Jerusalem, Israel
Contact: Arik Tzukert, DMD    00 972 2 6776095   
Contact: Hadas Lemberg, PhD    00 972 2 6777572    :   
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: liran horev, md Hadassah Medical Organization
Principal Investigator: rena cooper-kazaz, md Hadassah Medical Organization
Layout table for additonal information Identifier: NCT00532519    
Other Study ID Numbers: horcoop-hmo-ctil
First Posted: September 20, 2007    Key Record Dates
Last Update Posted: September 20, 2007
Last Verified: September 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Skin Diseases
Skin Diseases, Eczematous
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs